Study details
Enrolling now
REACT-01: Reversing Autoimmunity Through Cell Therapy
Seattle Children's Hospital
NCT IDNCT06465147ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
12
Study length
about 17 years
Ages
2–30
Locations
1 site in WA
What this study is about
This trial is testing a treatment for Systemic Lupus Erythematosus (SLE) in children and young adults. The treatment involves modifying T cells to target B cells, aiming to reverse the autoimmune condition.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive SCRI-CAR19v3
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Body systems
Immune